Isabela Dolci

Isabela Dolci

Auto-generated profile, based on publicly available information

Isabela Dolci

Sao Carlos Institute of Physics, University of Sao Paulo, Av. Joao Dagnone, Sao Carlos, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GNGabriela Dias Noske
Gabriela Dias Noske
ESEllen de Souza Silva
Ellen de Souza Silva
MGMariana Ortiz de Godoy
Mariana Ortiz de Godoy
IDIsabela Dolci
Isabela Dolci
RFRafaela Sachetto Fernandes
Rafaela Sachetto Fernandes
AGAndre Godoy
Andre Godoy
SARS-CoV-2 is the causative agent of COVID-19. The main viral protease (Mpro) is an attractive target for antivirals. The clinically approved drug nirmatrelvir and the clinical candidate ensitrelvir have so far showed great potential for treatment of viral infection. However, the broad use of antivirals is often associated with resistance generation. Herein, we enzymatically characterized 14 naturally occurring Mpro polymorphisms that are close to the binding site of these antivirals. Nirmatrelvir retained its potency against most polymorphisms tested, while mutants G143S and Q189K were associated with diminished inhibition constants. For ensitrelvir, diminished inhibition constants were observed for polymorphisms M49I, G143S, and R188S, but not for Q189K, suggesting a distinct resistance profile between inhibitors. In addition, the crystal structures of selected polymorphisms revealed interactions that were critical for loss of potency. In conclusion, our data will assist the monitoring of potential resistant strains, support the design of combined therapy, as well as assist the development of the next generation of Mpro inhibitors.

8 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
XNXiaomin Ni
Xiaomin Ni
RRR. Blake Richardson
R. Blake Richardson
AGAndre Godoy
Andre Godoy
MFMatteo P. Ferla
Matteo P. Ferla
CKCaroline Kikawa
Caroline Kikawa
FDFrank von Delft
Frank von Delft
The Zika viral protease NS2B-NS3 is essential for the cleavage of viral polyprotein precursor into individual structural and non-structural (NS) proteins and is therefore an attractive drug target. Generation of a robust crystal system of co-expressed NS2B-NS3 protease has enabled us to perform a crystallographic fragment screening campaign with 1076 fragments. 46 fragments with diverse scaffolds are identified to bind in the active site of the protease, with another 6 fragments observed in a potential allosteric site. To identify binding sites that are intolerant to mutation and thus suppress the outgrowth of viruses resistant to inhibitors developed from bound fragments, we perform deep mutational scanning of the NS2B-NS3 protease. Merging fragment hits yields an extensive set of ‘mergers’, defined as synthetically accessible compounds that recapitulate constellations of observed fragment-protein interactions. In addition, the highly sociable fragment hits enable rapid exploration of chemical space via algorithmic calculation and thus yield diverse possible starting points. In this work, we maximally explore the binding opportunities to NS2B-NS3 protease, facilitating its resistance-resilient antiviral development.